SPECTACL: SPECTroscopic Assessment of Coronary Lipid

Myocardial Infarction Clinical Trial

— SPECTACL  

Official title:

Coronary Artery Plaque Characterization by NIR Spectroscopy in Patients Undergoing Elective Percutaneous Coronary Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00330928
• Other study ID #: 0101
• Secondary ID: CL0101
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: January 2006
• Est. completion date: October 2008

Study information

• Verified date: December 2020
• Source: InfraReDx
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention (PCI).

Description:

Extensive studies conducted over the past 7 years in autopsy specimens have demonstrated that NIR spectroscopy can identify the plaque structures that are suspected to cause the acute coronary artery syndromes(unstable angina, myocardial infarction, and sudden death).

The application of NIR spectroscopy to identify lipid deposition within coronary arteries has shown promising results in preclinical ex vivo studies (14). Infrared spectra are collected as follows: light of discrete wavelengths from a laser is directed onto the tissue sample via glass fibers. Light scattered from the samples is collected in fibers and launched into a spectrometer. The plot of signal intensity as a function of wavelength can be then used to develop chemometric models to discriminate lipid-rich deposits from non-atherosclerotic tissue, and from atherosclerotic tissue that is predominantly fibrotic and from blood elements. This technique is incorporated into a thin catheter with similar dimensions to an IVUS catheter, and the intracoronary dwell time for analysis is similar to the broad experience with established techniques with proven safety, such as IVUS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: October 2008
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• >=18yrs and undergoing elective or non-emergent PCI of a de novo native coronary artery lesion

• Treatment plan (at time of consent and at time of intervention) must be to perform an intervention on no more than 2 lesions, where one is the culprit lesion and the other lesion requires revascularization at the discretion of the treating physician.

• Target lesion should have "low-risk" characteristics(defined by angiography)

• Subject must be able to read, understand and sign an approved informed consent form and follow protocol

• Female subjects of child bearing potential must have a negative serum pregnancy test prior to enrollment

Exclusion Criteria:

• Evidence of Clinical instability in the 6 hours before the procedure, or at any time during the procedure (72 hours stable post-STEMI)

• Angiographically Unsuitable Coronary and/or Lesion Morphology in the culprit vessel.

• A contraindication to anticoagulation or increased risk of bleeding.

• Clinically significant abnormal laboratory findings

• Presence of a drug eluting stent in the artery for experimental study prior to NIR measurement, unless all struts are covered by endothelium as documented by IVUS

• Elective PCI on or through bypass grafts or LIMA grafts

• Allergy or intolerance to aspirin or clopidogrel

• Planned use of laser ablation, rotational ablation, brachytherapy, or atherectomy device

• Enrollment or participation in any other medication trial within the previous 30 days

• Current enrollment participation or enrolled in another clinical trial

• Any other factor that the investigator feels would put the patient at increased risk if participating in the protocol

Related Conditions & MeSH terms

• Angina Pectoris
• Angina, Unstable
• Infarction
• Myocardial Infarction

Intervention

Device:
• Near Infrared Spectroscopy (NIRS) Imaging
Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
• intravascular ultrasound (IVUS)
Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.

Locations

Country	Name	City	State
Canada	Montreal Heart Institute	Montreal	Quebec
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Lahey Clinic	Burlington	Massachusetts
United States	Duke Medical Center	Durham	North Carolina
United States	Columbia University Medical Center	New York	New York
United States	William Beaumont Hospital	Royal Oak	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
InfraReDx

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Waxman S, Dixon SR, L'Allier P, Moses JW, Petersen JL, Cutlip D, Tardif JC, Nesto RW, Muller JE, Hendricks MJ, Sum ST, Gardner CM, Goldstein JA, Stone GW, Krucoff MW. In vivo validation of a catheter-based near-infrared spectroscopy system for detection o — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Spectral Similarity	Average spectral similarity of the spectra in a complete scan per patient as compared to the autopsy spectral data set.Clinical data was considered similar to autopsy data if average spectral similarity in each scan was >=67%, on a continuous range of 0%(different) to 100%(identical) similarity.	Baseline
Secondary	Review of Lipid Core Plaque of Interest Near Infrared Signals Observed at Baseline in Patients With Stable Angina vs Acute Coronary Syndromes	This is an exploratory examination to determine if an association exists between the presence or characteristics of lipid core plaques of interest signals and the clinical designation of acute or stable coronary artery disease in enrolled subjects. The study is not powered for statistical significance for this outcome.	Baseline
Secondary	Identification of Distinct Near Infrared Spectral Characteristics Associated With Special Coronary Artery Features Identified by Angiography and/or Intravascular Ultrasound and Patient Characteristics		Baseline
Secondary	Clinical Cardiac Events Definitely Attributable to the Study Device That Occur From Enrollment to 7 Days Post Enrollment	Major adverse cardiac events (MACE: myocardial infarction, cardiac surgery, death, cerebral vascular accident, coronary revascularization) will be evaluated for being categorized as Definitely attributable to the study device.	Baseline to 7 day
Secondary	Cardiac Events That Occur Within 1 Year Post Enrollment Will be Examined for Link to Lipid Signals.	Major adverse cardiac events (MACE: myocardial infarction, cardiac surgery, death, cerebral vascular accident, coronary revascularization) will be evaluated relation to baseline presence of lipid signals by near infrared spectroscopy. This study is not powered to reach statistical significance for this outcome.	1 year